ABBV
AbbVie Inc
AbbVie Inc historical holders
total: 14
Matrix Advisors Value Fund AbbVie Inc transactions over time
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 2
- Reduced:
- 9
- Held since:
- 2020 Q1
- Held for:
- 20 quarters
- Latest activity:
- 2024 Q3
David Katz has been an institutional investor in AbbVie Inc (ABBV) since 2020 Q1. According to 2024 Q4 report, David Katz holds 9,000 shares with a market value of roughly $1.60M representing 2.27% of their equity portfolio. The fund/company first acquired ABBV in 2020 Q1, initially purchasing 23,000 shares. Since the initial investment, Matrix Advisors Value Fund has made 11 more transactions in this position.
Does David Katz still hold ABBV?
Yes, David Katz continues to hold AbbVie Inc (ABBV). According to their 2024 Q4 report, they maintain a position of 9,000 shares valued at approximately $1.60M, representing 2.27% of their equity portfolio.
When did David Katz first invest in ABBV?
David Katz first invested in AbbVie Inc (ABBV) in 2020 Q1 at the reported quarter-end price of $76.19 per share, acquiring 23,000 shares in their initial purchase.
What is David Katz's average cost basis for ABBV?
Based on historical transaction data, David Katz's estimated cost basis for AbbVie Inc (ABBV) is approximately $78.35 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $78.35
- Weighted AVG sell price:
- $151.08
ABBV transactions history by Matrix Advisors Value Fund
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
2.57%
|
9,000
|
$197.48
|
$1,777,320
|
-12.62% (-1,300)
|
-0.39%
|
|
2024 Q1
|
2.89%
|
10,300
|
$182.10
|
$1,875,630
|
-9.65% (-1,100)
|
-0.33%
|
|
2023 Q4
|
2.92%
|
11,400
|
$154.97
|
$1,766,658
|
+4.59% (+500)
|
+0.13%
|
|
2023 Q2
|
2.58%
|
10,900
|
$134.73
|
$1,468,557
|
+1.87% (+200)
|
+0.05%
|
|
2022 Q4
|
3.38%
|
10,700
|
$161.61
|
$1,729,227
|
-10.08% (-1,200)
|
-0.4%
|
|
2022 Q2
|
3.44%
|
11,900
|
$153.16
|
$1,822,604
|
-12.50% (-1,700)
|
-0.39%
|
|
2022 Q1
|
3.34%
|
13,600
|
$162.11
|
$2,204,696
|
-30.61% (-6,000)
|
-1.38%
|
|
2021 Q4
|
3.77%
|
19,600
|
$135.40
|
$2,653,840
|
-1.51% (-300)
|
-0.06%
|
|
2020 Q4
|
3.97%
|
$107.15
|
-1.97% (-400)
|
|||
|
2020 Q3
|
3.76%
|
$87.59
|
-5.14% (-1,100)
|
|||
|
2020 Q2
|
4.36%
|
$98.18
|
-6.96% (-1,600)
|
|||
|
2020 Q1
|
4.44%
|
$76.19
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.